SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-029426
Filing Date
2024-06-24
Accepted
2024-06-24 06:35:21
Documents
17
Period of Report
2024-06-24
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20240624.htm   iXBRL 8-K 28070
2 EX-99.1 a208finalanalysis_update.htm EX-99.1 9176
6 a208finalanalysis_update001.jpg GRAPHIC 248136
7 a208finalanalysis_update002.jpg GRAPHIC 284211
8 a208finalanalysis_update003.jpg GRAPHIC 39005
  Complete submission text file 0001628280-24-029426.txt   956381

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20240624.xsd EX-101.SCH 1922
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20240624_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20240624_pre.xml EX-101.PRE 13060
20 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20240624_htm.xml XML 2833
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 241061929
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)